Mesenchymal stem cells (MSCs) are multipotent stromal cells that can be isolated from numerous tissues, with the most studied sources being the bone marrow, skeletal muscle, amniotic fluid, and adipose tissue ([@bib1]--[@bib3]). By definition, MSCs must meet the following requirements: *1*) adherence to plastic; *2*) trilineage differentiation into adipocytes, chondrocytes, and osteoblasts; and *3*) expression of cell-surface mesenchymal markers (CD105, CD90, CD73, CD13, CD166, CD44, and CD29) and a lack of expression of hematopoietic and endothelial surface markers (CD45, CD31, and CD34) ([@bib4]).

Furthermore, key unique features of MSCs are their ability to repair tissue through paracrine support of injured cells, partially due to their transfer of mitochondria into damaged cells (i.e., alveolar epithelium), and their ability to modulate the immune response in a paracrine manner through the production of a range of immunomodulators (such as TGF-β \[transforming growth factor β\], PGE2 \[prostaglandin E2\], IL-10, nitric oxide, and indoleamine 2,3-dioxygenase) and the inhibition of T-cell proliferation ([@bib5]). All of these features point toward MSCs as one of the most useful cell sources for clinical application in tissue regeneration and cell therapy, with a low risk compared with embryonic stem cells because of their minimal risk of tumor formation and low immunogenicity ([@bib6]).

Accordingly, the transfer of MSCs has been proposed as a therapeutic tool for acute and chronic lung injuries, and has been successful in animal models of endotoxin-induced acute respiratory distress syndrome, where MSCs decreased alveolar leakage, suppressed inflammation, and improved survival ([@bib7]--[@bib11]). In a murine model of bleomycin-induced lung fibrosis, the systemic administration of MSCs was shown to be effective in preventing the development of lung fibrosis ([@bib12]--[@bib14]).

A key feature of adult stem cells in general is that they reside in specific anatomical sites or niches (i.e., bone marrow) that preserve their potential, regulate their proliferation, and inhibit their differentiation, preserving their stemness throughout life ([@bib15]). The decision to lie dormant, self-renew, or differentiate is a consequence of the diverse cocktail of signals provided by the stem cell niche. Recent studies have proposed that the niche not only affects the homeostatic pool of the stem cells but also profoundly affects the functionality and behavior of the cells ([@bib15]--[@bib17]). In this context, the microenvironment in which the MSCs reside acts as a director that modifies their functionality ([@bib18]). In fact, the environment can drive these cells to the fully functional immunosuppressive MSC phenotype or to a "proinflammatory" (impaired in repair) phenotype ([@bib19]). Key factors in this phenotype modulation are the extracellular matrix itself, as well as reactive oxygen species (ROS) (oxidative stress). Specifically, increased ROS inhibit MSC proliferation, increase senescence, enhance adipogenesis but reduce osteogenic differentiation, and inhibit MSC immunomodulation.

Previous studies have shown that exposure to disease-associated ROS in atherosclerosis and type 2 diabetes impairs the immunomodulatory capacity of MSCs ([@bib20], [@bib21]). In this issue of the *Journal*, Islam and colleagues (pp. [1214--1224](10.1164/rccm.201802-0356OC)) contribute to the concept of the microenvironment as a key factor in shaping the function of MSCs in the treatment of lung injuries ([@bib22]). In their study, they induced three different conditions of lung injury with different microenvironments: *1*) intratracheal instillation of hydrochloric acid (HCl), *2*) mechanical ventilation, and *3*) two-hit injury (combining HCl and mechanical ventilation). In these three different injured conditions there were different responses, ranging from no effect to beneficial or detrimental effects, directly after the administration of MSCs. This shows that the microenvironmental modulation of the MSC phenotype takes place *in vivo*. Specifically, in the case of mechanical injury alone, MSC transfer reduced lung injury and fibrotic changes, whereas in mice that received HCl, with or without ventilation, it resulted in greater fibrotic changes (Ashcroft score) and inhibited reepithelialization. The authors were able to demonstrate that MSCs were protective in the HCl model if they were given 14 days after injury, by removing the proinflammatory microenvironment.

Finally, the authors demonstrated that modulation of the microenvironment can be done concomitantly with MSC transfer, either by GPx-1 administration (correcting the oxidative stress) ([@bib23]) or by the MSCs themselves when modified to carry human hepatocyte growth factor or human IL-10.

The observations presented in this study are critical, based on the concept that with any therapy we need to prevent harm to the lung. It is reasonable to conclude that the characterization, identification, and optimization of the lung microenvironment would improve the efficacy of MSCs in the treatment of acute respiratory distress syndrome, as well as many other injuries in which there is a proinflammatory microenvironment with a high level of oxidative stress. Interestingly, the data support the need to develop a "second generation" of MSCs, in which MSCs are modified to specifically enhance their therapeutic effect by overexpressing antiinflammatory molecules (IL-10) and protective molecules (hepatocyte growth factor) or by use of microRNAs to regulate protein expression in specific target cells ([@bib24]), that can lead to a more "secure" and highly effective MSC-based lung therapy.
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